CytoDyn to Hold Webcast on July 22 to Discuss Results from Cancer Trials, HIV BLA Status, NASH, and COVID-19 Trials Jul 19, 2021 4:41pm EDT
CytoDyn Announces Preliminary Results from 30 mTNBC Patients Treated with Leronlimab. Decreases in CAMLs after 4 Doses of Leronlimab were Identified in Over 70% of Patients and were Associated with a 450% Significant Increase in Overall Survival at 12-Month Analysis Jul 19, 2021 6:00am EDT
CytoDyn’s Trial for Metastatic Triple-Negative Breast Cancer Demonstrates Safety with 350 mg, 525 mg and 700 mg Dosages; Officially Advances to Phase 2 from Phase 1b Jul 12, 2021 6:00am EDT
CytoDyn Granted a Significant Patent by USPTO for Methods of Treating Coronavirus Infection with Leronlimab Jul 06, 2021 6:00am EDT
CytoDyn Submits Dose Justification Report to FDA to Begin Overcoming Deficiencies in its BLA for HIV Jul 01, 2021 6:07pm EDT
CytoDyn Inc. Announces Positive Preliminary Results of Unblinded Data from Long-Haulers Trial Showing Greater Improvement in Leronlimab Group over Placebo in 18 of 24 Symptoms Jun 21, 2021 8:30am EDT
CytoDyn to Hold Webcast on June 21 to Discuss Unblinded Data from COVID-19 Long-Haulers Trial and Other Developments Jun 16, 2021 4:01pm EDT
Nature Communications Publishes Study of CytoDyn’s Leronlimab Preventing HIV Infection in Primates Jun 07, 2021 8:51am EDT
CytoDyn and Philippine Airlines Work Together to Provide Filipinos with the Best Possible Treatment Options In the Fight Against Covid-19 Jun 01, 2021 9:23am EDT
CytoDyn Receives First Purchase Order from Chiral Pharma Corporation for Use of Leronlimab Under CSP for COVID-19 Patients in the Philippines Jun 01, 2021 9:15am EDT
